Monocyte Transcriptional Reprogramming Explains Refractory In-Stent Restenosis Authors: Joseph Bednarek, Juan Ibla, Edward B. Thorp Published: 2026 Refractory repeated in-stent restenosis (RISR), or recurrent renarrowing of the coronary artery lumen following percutaneous intervention, remains a challenging patient burden in interventional cardiology.1 Although conventional restenosis is typically attributed to poor mechanical stent expansion, neointimal hyperplasia, or neoatherosclerosis, persistent or refractory cases frequently defy therapies.2 Lipid-lowering drugs, statins, and standard dual antiplatelet regimens regularly fail to treat RISR.3,4 This cycle of failure is consistent with an underlying nonresolving inflammatory microenvironment within the vessel wall that continuously drives cellular proliferation and tissue remodeling, making revascularization an insufficient solution.4 In general, patients presenting with RISR were rarely suspected of having a primary autoimmune or inflammatory arteritis as an underlying cause.3 As such, potential immunopathogenesis has gone unaddressed, permitting localized leukocyte infiltration and cellular activation directly around the stent and inevitably predisposing the vessel to repeated failure. Isolated coronary arteritis (ICA) is a localized vasculitis in which inflammation is confined to coronary arteries. Because ICA is entirely confined to the coronary tree, it lacks systemic inflammatory biomarkers and the multiorgan manifestations typical of other vascular disorders.5 Consequently, it mimics aggressive, conventional atherosclerosis or atypical neoatherosclerosis. The similarities between ICA and RISR are unmistakable and prompted further investigation. In this issue of JACC: Basic to Translational Research, Yu et al6 shed light on the molecular mechanisms of ICA-RISR vascular pathologies. By leveraging the high-resolution capabilities of single-cell transcriptomics, the investigators avoid the limitations of traditional bulk tissue analysis to define the coronary immune landscape at single-cell resolution. Their subsequent ICA-RISR experiments then identified a molecular culprit: monocyte transcription factor, activator protein (AP)-1.7,8 Through rigorous functional validation, the investigators revealed evidence that this single transcriptional switch turns infiltrating monocytes destructive through excessive proinflammatory cytokine secretion. These cytokines fuel the localized inflammatory environment around stents and ultimately coronary artery failure. To further investigate underlying mechanisms of ICA-RISR, Yu et al6 first mapped the immune landscape of coronary blood mononuclear cells of patients. Single-cell RNA sequencing was carried out on lesions from RISR and non-ISR patients that met strict diagnostic criteria. Although the transcriptional composition of immune cells remained unchanged between these groups, high-resolution subclustering identified a pervasive, cross-subset transcriptional reprogramming within the monocyte lineage. In these cells, the investigators identified significant up-regulation of the AP-1 transcription factor complex (specifically its JUN and FOS subunits). In turn, they defined a signaling cascade in which elevated expression of the C-C motif chemokine receptor 1 (CCR1) receptor on ICA-RISR monocytes sensitized the cells to microenvironmental CCL5 stimulation, triggering the p38 mitogen-activated protein kinase (MAPK) signaling pathway to lock the AP-1 complex into an active state. Once activated, ICA-RISR monocytes excessively secreted proinflammatory cytokines, notably CXCL8, CCL3, and interleukin-1β (Figure 1). Yu et al6 explain that these monocyte-derived, proinflammatory cytokines perpetuate the inflammatory environment necessary for RISR lesions.Figure 1Monocyte Transcription FactorAP-1 Activation Promotes Inflammatory Isolated Coronary Arteritis (ICA)-Refractory Repeated In-Stent Restenosis (RISR)Increased expression of monocyte C-C motif chemokine receptor 1 (CCR1) sensitizes monocytes to CCL5 in the coronary artery microenvironment. Binding of CCR1 results in p38 mitogen-activated protein kinase (MAPK) signaling that activates the transcription factor, AP-1. Chronic activation of AP-1 leads to hyper-expression of pro-inflammatory cytokines including CCL3, CXCL8, IL-1β. Figure created in BioRender. ERK = extracellular signal-regulated kinase; HCASMCs = human coronary artery smooth muscle cells; IL = interleukin; ISR = in-stent restenosis; JNK = c-Jun N-terminal kinase. Monocyte Transcription FactorAP-1 Activation Promotes Inflammatory Isolated Coronary Arteritis (ICA)-Refractory Repeated In-Stent Restenosis (RISR) Increased expression of monocyte C-C motif chemokine receptor 1 (CCR1) sensitizes monocytes to CCL5 in the coronary artery microenvironment. Binding of CCR1 results in p38 mitogen-activated protein kinase (MAPK) signaling that activates the transcription factor, AP-1. Chronic activation of AP-1 leads to hyper-expression of pro-inflammatory cytokines including CCL3, CXCL8, IL-1β. Figure created in BioRender. ERK = extracellular signal-regulated kinase; HCASMCs = human coronary artery smooth muscle cells; IL = interleukin; ISR = in-stent restenosis; JNK = c-Jun N-terminal kinase. What elevates this study is the rigorous validation experiments that followed their single-cell sequencing. The experimental design not only demonstrates the critical role of ICA-RISR monocytes but also clarifies how the pathophysiology is interlinked. The investigators confirmed the up-regulation of this CCR1/p38/AP-1 signature and its downstream chemokines in an independent clinical validation cohort using orthogonal wet-lab assays (including flow cytometry, Western blot, and enzyme-linked immunosorbent assay). Also demonstrated was the cell-intrinsic nature of the phenotype through coculture assays, showing that AP-1-activated monocytes directly trigger the pathologic proliferation and migration of human coronary artery smooth muscle cells (HCASMCs), an indicator of vascular remodeling. Interestingly, when monocyte AP-1 was blocked with a pharmacologic inhibitor, the vascular remodeling of HCASMCs was completely reversed. Demonstrating that monocytes isolated directly from RISR patients enhance the proliferation and migratory capacity of HCASMCs provides functional proof of cellular crosstalk. In vivo, and using a wire-induced murine vascular injury model, bone marrow-specific knockdown of the master Fos subunit successfully halted neointimal hyperplasia, minimized luminal stenosis, and prevented the pathologic smooth muscle phenotypic switch. Monocyte-specific knockdown of the Fos subunit using a targeted virus carrying an shRNA-miR30 sequence demonstrated that silencing this single transcriptional node directly suppresses neointimal hyperplasia. Collectively, these findings establish the monocyte AP-1 pathway as an important, targetable checkpoint in the pathogenesis of refractory stent failure. This work provides a novel, systematic, high-resolution immunologic characterization of ICA-RISR. By focusing specifically on this rare and challenging clinical intersection, the investigators have mapped largely uncharted territory in this space within interventional cardiology. Single-cell tissue studies are frequently criticized for small, poorly defined cohorts. Here, the investigators implemented exceptionally strict parameters to define their RISR and control groups. They avoided single-batch bias by confirming their initial findings across entirely separate discovery and validation cohorts, adding statistical weight to their data. Identifying the aberrant activation of the monocyte CCR1/p38 MAPK/AP-1 pathway provides the field with a signaling cascade to study and target with therapeutics. Although the study uncovers deep transcriptional variations within monocyte subsets, the global single-cell profiling failed to show any significant differences in broad cell-type distributions between individual cohorts. These computationally derived cell-type distributions were not independently validated using conventional quantitative methods such as flow cytometry or immunohistochemistry. This leaves an unverified gap between the algorithmic cell clustering and the actual physical proportions within the coronary microenvironment. Flow validation of all cells, not just monocytes, may reveal important additional information about RISR immunopathology. The data also show reductions in alpha-smooth muscle actin to support conclusions on smooth muscle cell phenotypic switching. However, a decrease in alpha-smooth muscle actin expression alone is not a universal proxy for such a switch.9 This reduction could be confounded by local extracellular matrix remodeling, variations in tissue sectioning planes, or the physical displacement of contractile tissue by dense, invading inflammatory infiltrates.10 Without a broader, multimarker panel, labeling this structural signal drop as definitive differentiation requires caution. Although the investigators establish a causative molecular pathway for ICA-RISR, their findings raise critical questions for future clinical translation. First, the underlying genetic, epigenetic, or environmental variations that prime specific individuals for this hyper-reactive monocyte response remain unknown. Second, because ICA operates without systemic inflammatory markers, future studies may evaluate whether a targeted panel measuring circulating CXCL8, CCL3, or monocyte CCR1 expression can serve as a noninvasive screening tool to detect subclinical arteritis before stent failure occurs. Moreover, it remains unclear what role chronic mechanical stress plays in ICA-RISR. Future research in this space can determine whether the localized physical strain and shear stress imposed by stents act as the primary biophysical trigger that ignites the p38 MAPK/AP-1 inflammatory cascade. Ultimately, this study by Yu et al6 contributes to the evolving blueprint for precision cardio-immunology by redefining ICA-RISR as a highly coordinated immunologic event rather than a purely mechanical or hyperplastic failure. By linking patient-derived single-cell transcriptomics to in vivo vascular remodeling, this work establishes the CCR1/p38 MAPK/AP-1 pathway in monocytes as the likely cause of this persistent clinical problem (Figure 1). Although directly drugging transcription factors remains a historical challenge, this work identifies clear therapeutic vulnerabilities, whether through upstream CCR1 antagonism or downstream cytokine neutralization, to halt the smooth muscle phenotypic switching that drives ICA-RISR. This study contributes to shifting the old paradigm away from systemic immunosuppression to more targeted, cell-specific strategies capable of breaking the cycle of recurrent stent failure. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.